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e-mail address: drghasemi@yahoo.com (K.G. Falavarjani).Khalil Ghasemi Falavarjani ⇑, Ali Khoshamadi, Naveed NilforushanAbstractPurpose: To evaluate the effect of macular photocoagulation (MPC) on peripapillary nerve fiber layer (PNFL) thickness measure-
ment in patients with clinically significant diabetic macular edema (CSME).
Methods: This study was a prospective interventional case series. Patients with CSME underwent MPC. Optical coherence tomog-
raphy (OCT) was used to measure the PNFL and central macular thicknesses before and 3 months after MPC.
Results: Thirty-three eyes of 25 patients with a mean age of 59.4 ± 7.2 years were included. There was no statistically significant
difference between pre- and post-MPC mean best corrected visual acuity (0.35 ± 0.29 and 0.40 ± 0.23 LogMAR, respectively,
P = 0.2). Mean baseline and 3 months central macular subfield thickness was 305.9 ± 90.7 and 317.5 ± 112.4 microns, respectively
(P = 0.1). Peripapillary nerve fiber layer thickness was 105.7 ± 10.0 before and 106.1 ± 9.9 three months after MPC (P = 0.7). No
significant differences were found between pre and post MPC measurements in temporal, nasal, inferior and superior nerve fiber
layer thickness in each quadrant around optic nerve head (P > 0.05).
Conclusions: Macular photocoagulation has no statistically significant effect on PNFL thickness measurements in patients with
CSME.
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Macular edema is one of the most common causes of
visual impairment in patients with diabetic retinopathy.1 Early
Treatment Diabetic Retinopathy Study (ETDRS) demon-
strated the benefit of macular photocoagulation (MPC) treat-
ment on reducing the risk of moderate visual loss in eyes with
clinically significant macular edema (CSME).2 Although signif-
icant changes have occurred in the management of diabetic
retinopathy, recent studies have shown the efficacy of
focal/grid laser alone in eyes with non-center involved CSME
or as an adjunct to intravitreal pharmacotherapy.3–5Despite beneficial effect of MPC, it may be associated
with considerable side effects, such as atrophic scarring caus-
ing paracentral dense scotomas, generalized loss of the
visual field sensitivity, choroidal neovascularization, and sub-
foveal fibrosis.6–11 Significant changes have been reported in
the visual field of patients with CSME after MPC.9–11 Since
testing the visual field is one of the main parts of the diagno-
sis and management of glaucoma, the field defects after
MPC may erroneously affect the decisions.
Optical coherence tomography (OCT) has become an
integral part of the diagnosis and management of glaucoma
and retinal disease. Measurement of peripapillary nerve fibere:
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sively glaucomatous nerve changes and disease progres-
sion.12–14 Although previous studies using OCT reported
the changes in the PNFL thickness measurements in eyes with
diabetic retinopathy with and without CSME, the effect of
MPC on PNFL thickness has not been evaluated.15,16 The
aim of this study was to evaluate the effect of MPC on PNFL
thickness measurements in patients with CSME.Subjects and methods
In this prospective interventional case series, from May to
October 2012, all patients with clinically significant diabetic
macular edema (according to EDTRS classification)2 who
underwent MPC were included. We considered MPC for eyes
with non-center involved macular edema. Patients who were
eligible for intravitreal anti-vascular endothelial growth
factor (VEGF) therapy but rejected the injections were alsoFigure 1. Pre- and post-laser treatment optical coherence tomography of a p
Central subfield thickness of 352 microns (A) improved to 250 microns (B). S
layer thickness was 112 microns before (E) and 109 microns (F) after laser treconsidered for MPC treatment. The study protocol was
approved by the Rasoul Akram Hospital Eye Research Center
Ethics Committee. Informed consents were obtained.
Exclusion criteria were history of intraocular surgery or
laser photocoagulation during the last 8 months, high refrac-
tive errors (>6 diopters of sphere or >3 diopters of cylinder),
media opacity affecting visual acuity and OCT measure-
ments, history of glaucoma, ischemic or inflammatory optic
neuropathy, uveitis, retinal vascular occlusion, disk shape
abnormalities or large peripapillary atrophy, intraocular pres-
sure more than 22 mmHg, vitreomacular interface disorders
and the need for panretinal photocoagulation or anti-VEGF
therapy during follow up. Both eyes of each participant were
enrolled if both eyes met the inclusion criteria.
Baseline examinations included best corrected visual acu-
ity measurement (BCVA) using a standard Snellen chart (con-
verted to Log MAR), slit lamp and dilated fundus
examinations, tonometry with a calibrated Goldmannatient with center involving clinically significant diabetic macular edema.
ubretinal fluid (C) resolved completely (D). Total peripapillary nerve fiber
atment.
Table 1. Peripapillary nerve fiber layer measurement before and after







fiber layer thickness (l)
105.7 ± 10.0 106.1 ± 9.9 0.7
Nasal peripapillary nerve
fiber layer thickness (l)
89.7 ± 18.2 91.5 ± 17.2 0.7
Temporal peripapillary nerve
fiber layer thickness (l)
85.6 ± 16.9 86.2 ± 18.1 0.4
Inferior peripapillary nerve
fiber layer thickness (l)
124.6 ± 23.8 125.6 ± 16.7 0.7
Superior peripapillary nerve
fiber layer thickness (l)
122.8 ± 16.8 123.0 ± 18.7 0.9
a Paired t test.
Effect of macular photocoagulation on PNFL thickness 69applanation tonometer, fluorescein angiography (FA) and
OCT measurements. Peripapillary nerve fiber layer and mac-
ular thickness measurements were performed with a 3D spec-
tral domain OCT-1000 device (software version 3.32.003.04,
Topcon corporation, Tokyo, Japan). A 3D Scan 512  128
protocol, covering 6  6 mm2 centered on optic disk or fovea
was used for all measurements. Using a 3.4 mm diameter cir-
cle around the ONH, the measurements were automatically
averaged to yield 12 clock-hour thicknesses, four quadrant
thicknesses, and a global average PNFL thickness measure-
ment. This device has shown good intra- and interobserver
reproducibility in PNFL measurements.17
Good quality scans had to have focused images from the
ocular fundus, adequate quality factor (>45), and the pres-
ence of a centered circular ring around the optic disk. Images
with discontinuity, misalignment, involuntary saccade or
blinking artifacts were excluded. OCT imaging was per-
formed immediately before and 3 months after MPC by
one expert technician.
A modified EDTRS protocol was used for laser photocoag-
ulation.18 Briefly, barely visible, 50 micron size argon laser
burns, with a duration of 0.1 s and 2 visible burn widths apart
were placed for grid treatment in all areas of retinal thicken-
ing. In addition, focal non-bleaching laser treatment of micro-
aneurysms was performed in all eyes. Baseline examinations
except for FA, were repeated at 3 months post treatment
visit. All laser treatments were performed by one retina spe-
cialist (A.K.).
Sample size of 32 eyes was calculated to find a difference
of 5 microns in PNFL measurements with a study power of
80%.
All Statistical analyses were performed with SPSS software
(version 15, SPSS Inc. Chicago, IL) and paired t test was used
for analysis. P < 0.05 was considered significant.Results
Thirty-three eyes of 25 patients with type 2 diabetes
including 13 females and 12 males with a mean age of
59.4 ± 7.2 years were studied. The mean duration of diabetes
was 11.7 ± 4.8 years and 16 patients had history of hyperten-
sion. Macular edema was foveal center involving in 24 eyes
(72.7%). Among 9 eyes without center involvement, macular
edema was present in all quadrants in 5 eyes, in 2 quadrants
in 2 eyes and in 1 quadrant in 2 other eyes. Mean retinal
thickness in central subfield, temporal, nasal, superior and
inferior 3 mm ETDRS quadrants was 305.9 ± 90.7,
355.7 ± 59.9, 336.9 ± 45.9, 357.6 ± 57.7 and 343.9 ± 54
microns, respectively.
Mean total laser spot number was 198.9 ± 69 and mean
laser spot number in temporal, nasal, superior and inferior
quadrants was 79.9 ± 40.1, 15.7 ± 15.4, 63.7 ± 37.4 and
45.6 ± 38.3.
Mean BCVA was 0.35 ± 0.29 LogMAR at baseline (range
20/400–20/25 Snellen acuity) and 0.40 ± 0.23 LogMAR at
3 months after MPC (P = 0.2). Visual acuity improvement of
at least one line was observed in 6 eyes (18.1%). In 8 eyes
(24.2%) the visual acuity remained at the baseline level. Mean
baseline and 3 months central macular subfield thickness was
305.9 ± 90.7 and 317.5 ± 112.4 microns, respectively
(Fig. 1A–D, P = 0.1). Five eyes (15.1%) had a decrease in cen-
tral subfield thickness of P25 microns.The average and 4 quadrant PNFL measurements are
shown in Table 1. No significant differences were found
between pre and post laser treatment PNFL measurements
(Fig. 1E and F).Discussion
Results of the ETDRS showed focal MPC of eyes with
CSME reduced the risk of moderate visual acuity loss
(defined as a loss of P3 or more lines) by approximately
50% (from 24% to 12%) three years after initiation of treat-
ment.2 Although new treatment strategies including intravi-
treal injection of anti-VEGF agents and steroids have been
shown to be highly effective in the treatment of diabetic mac-
ular edema, MPC remained a widely used treatment for non-
center involved CSME and showed to be able to stabilize the
visual acuity.3 It is also used as an adjunct to intravitreal injec-
tion of anti-VEGF drugs for naïve eyes or eyes with persis-
tence diffuse CSME.4,5
Our results showed that 18% of eyes had a visual improve-
ment of P1 line and 15% had a decrease in central subfield
thickness of P25 microns. These are in accordance with a
recent study from Diabetic Retinopathy Clinical Research
Network that reported a 19% of visual improvement of P1
line and 18% of reduction in central subfield thickness of
P25 microns.3
Patients with diabetic retinopathy are at risk of developing
glaucoma.19 The measurement of visual field in eyes with
glaucoma and coexisting diabetic retinopathy often is
affected by retinal hemorrhage, exudates, and diabetes-
associated retinal nerve fiber loss.20 Previous studies have
shown that MPC results in visual field defects in automated
perimetry in a significant number of patients.9–11 Although
optic nerve head assessment has been reported to have
higher diagnostic value in glaucoma screening and manage-
ment in patients with diabetic retinopathy, the effect of
MPC on PNFL measurements has not been reported.15 Our
results showed that no significant changes occurred after
MPC in total PNFL measurements. Also, nerve fiber layer
measurements remained the same for each quadrant around
the optic nerve head. Based on these results, the PNFL mea-
surements may be considered reliable in the screening and
management of patients with CSME after MPC.
Previous studies have shown that the inner retinal layers
appear damaged after laser photocoagulation.21 Retinal
lesions have been shown to stabilize by 60 days in rats.22
So, we considered that 3 months is enough for repeating
70 K.G. Falavarjani, N. Nilforushanthe OCT measurements to assess the effect of laser
photocoagulation.
Our study has some limitations. We did not compare our
findings with normal controls. We did not perform the visual
field perimetry in our patients. Considering a control group
of patients with coexisting glaucoma and CSME, with the
same method of treatment, may further confirm the stability
of PNFL measurements after MPC. Also, patients with differ-
ent protocols of laser photocoagulation may show different
results. Although patients with severe CSME are usually trea-
ted with intravitreal anti-VEGF agents, the macular laser
treatment may be needed and the effect of laser treatment
on retinal layers may be different. Since our patients had mild
to moderate CSME, our results may not be applicable to this
subset of patients.
In conclusion, MPC does not change the PNFL measure-
ments. This finding may be considered valuable for the diag-
nosis and management of glaucoma in patients with CSME
treated with MPC. Future studies with larger sample size,
longer follow up and a control group are needed to confirm
our results.Conflict of interest
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